entecavir / Generic mfg. - LARVOL DELTA

An HBV-Derived Peptide Poly6 as a Novel Candidate for Functional Cure Via IFN-I-Mediated Epigenetic Regulation of cccDNA. (PubMed, J Med Virol) - "Poly6 also showed synergistic antiviral effects with entecavir...Chromatin immunoprecipitation confirmed reduced acetylation of H3K27, H4K5, and H4K12 on cccDNA minichromosomes. These results delineate a unified IFN-I-centered cascade in which Poly6 coordinates complementary antiviral activities, supporting its translational potential as a therapeutic candidate for durable HBV control."

Journal • Hepatitis B • Infectious Disease • Inflammation • IFI16 • STING

Fanconi syndrome induced by zoledronic acid: Two case reports. (PubMed, Medicine (Baltimore)) - "These cases highlight the importance of early recognition and close monitoring of renal tubular function in patients receiving ZA. Screening for FS, including urinalysis, blood gas analysis, and serum electrolytes, should be considered within the first month of therapy and repeated regularly thereafter. Clinicians should maintain high vigilance for FS, especially when ZA is used concurrently with other nephrotoxic agents such as adefovir."

Journal • Genito-urinary Cancer • Hepatitis B • Infectious Disease • Metabolic Disorders • Nephrology • Oncology • Prostate Cancer • Renal Disease • Solid Tumor

EFFECTIVENESS OF A STRUCTURED PREVENTION STRATEGY FOR HBV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING HBSAG-POSITIVE DONORS (EBMT 2026) - P=N/A | "Donors with detectable HBV DNA received entecavir 0.5 mg/day until completion of stem cell collection... This prospective study demonstrates that a novel HBV management strategy is feasible and associated with excellent hepatic safety, with no liver-related mortality observed. Although HBVr occurred, it was clinically manageable. Substantial heterogeneity in HBVr risk was observed among HBsAg-negative recipients with different baseline serologic profiles, providing important insights for the future refinement of risk-stratified preventive strategies."

Bone Marrow Transplantation • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Transplantation

EFFECTIVENESS OF A STRUCTURED PREVENTION STRATEGY FOR HBV REACTIVATION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION USING HBSAG-POSITIVE DONORS (EBMT 2026) - P=N/A | "Donors with detectable HBV DNA received entecavir 0.5 mg/day until completion of stem cell collection... This prospective study demonstrates that a novel HBV management strategy is feasible and associated with excellent hepatic safety, with no liver-related mortality observed. Although HBVr occurred, it was clinically manageable. Substantial heterogeneity in HBVr risk was observed among HBsAg-negative recipients with different baseline serologic profiles, providing important insights for the future refinement of risk-stratified preventive strategies."

Bone Marrow Transplantation • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Transplantation

Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOP (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Ou Bai, MD/PHD

New P3 trial • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatitis B • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

CLINICAL OUTCOMES AND MORTALITY PREDICTORS IN HEPATITIS B AND C POSITIVE CHRONIC LIVER DISEASE PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS IN RESOURCE-LIMITED SETTINGS: A PROSPECTIVE COHORT STUDY (ISN-WCN 2026) - "Direct-acting antivirals (glecaprevir/pibrentasvir or sofosbuvir/velpatasvir) were used for HCV; entecavir or tenofovir alafenamide/disoproxil for HBV with renal dosing. Annual HBV vaccination (89.5% seroprotection) and strict segregation reduced incident infections to zero in segregated units.Conclusion Low albumin and cirrhosis predicted mortality in HBV/HCV-positive CLD patients on MHD. Vaccination, segregation, and timely antiviral therapy were safe, feasible, and associated with improved virologic and survival outcomes in resource-limited dialysis settings."

Clinical • Clinical data • Chronic Kidney Disease • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Renal Disease

TELITACICEPT TREATMENT FOR IGA NEPHROPATHY AFTER LIVER TRANSPLANTATION: A CASE REPORT (ISN-WCN 2026) - "Postoperatively, he received long-term maintenance immunosuppressive therapy with tacrolimus, mycophenolate mofetil, and meprednisone, along with concurrent antiviral therapy for hepatitis B. Regular follow-up after the transplant showed no signs of proteinuria or renal function abnormalities...Treatment and Follow-up ProtocolAfter confirming the renal pathological diagnosis of IgA nephropathy (IgAN, M0E0S0T2C0), the patient was started on a targeted treatment regimen: Telitacicept at an initial dose of 160 mg per week combined with entecavir for continuous antiviral therapy... renal function indicators included blood urea nitrogen 10.37 mmol/L, creatinine 186.84 μmol/L, uric acid 598.43 μmol/L, and estimated glomerular filtration rate (eGFR) 35.99 mL/min/1.73m2; 24-hour urinary protein quantification was 2.1 g/24h, and urinalysis indicated 2+ urinary protein and 0-3 red blood cells per high-power field (HP) under microscope; serum IgA was 4.02 g/L; hepatitis B virus..."

Case report • Clinical • Cardiovascular • Chronic Kidney Disease • Fibrosis • Focal Segmental Glomerulosclerosis • Gastroenterology • Glomerulonephritis • Hematological Disorders • Hepatitis B • Hepatology • Hypertension • IgA Nephropathy • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Lupus Nephritis • Renal Disease • Transplant Rejection • Transplantation • MPO

Host-viral interaction of HBV infection revealed by single-cell transcriptome jointly profiling the viral replication state. (PubMed, Hepatology) - "In summary, our B-BEST platform provides resources for delineating the heterogeneous landscape of HBV infection, identifying host determinants and microenvironmental factors that govern viral replication and persistence, and highlighting hepatocyte proliferation as a potential clearance mechanism for antiviral therapy."

Journal • Hepatitis B • Infectious Disease • Inflammation

Ishak stage 6 fibrosis is more likely to regress than stage 5 in CHB patients undergoing entecavir therapy. (PubMed, Front Med (Lausanne)) - P4 | "Among CHB patients treated with ETV, those with baseline Ishak stage 6 were more likely to achieve histological fibrosis regression than those with stage 5. Identifier NCT01965418."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation

Serum sIL-2R Predicts Significant Histological Disease in Indeterminate Phase Chronic Hepatitis B. (PubMed, Int J Infect Dis) - "sIL-2R effectively identifies significant histological disease in IM patients. The derived nomogram aids risk stratification, while dynamic sIL-2R monitoring reflects therapeutic response, supporting its clinical utility."

Journal • Hepatitis B • Infectious Disease • Inflammation • IL2RA

Seronegative Cryoglobulinemic Glomerulonephritis Coexisting With Primary Sjögren Syndrome and HBV Infection: A Diagnostic and Therapeutic Challenge. (PubMed, Kidney Med) - "The patient was first treated with entecavir for HBV suppression, followed by pulse steroids and rituximab, resulting in resolution of kidney dysfunction and proteinuria. The coexistence of pSS and HBV can trigger CryoGN. A multidisciplinary and individualized therapeutic approach (antiviral and immunosuppressive) can lead to an excellent renal response."

Journal • Complement-mediated Rare Disorders • Glomerulonephritis • Hepatitis B • Hepatitis C • Immunology • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • Sjogren's Syndrome

Related Factors for Low-Level Viremia and the Comparative Efficacy of Management Strategies in Treatment-Naïve Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir Amibufenamide: A Real-World Study (APASL 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Comparative Efficacy of Entecavir and Tenofovir Disoproxil Fumarate in Preventing HBV Reactivation in Patients Receiving Biologic Diasease-Modifying Antirheumatic Drugs (APASL 2026) - No abstract available

Clinical • Hepatitis B

An Evaluation of the Effectiveness of Entecavir in Patients with Acute Chronic Hepatitis B liver Failure (APASL 2026) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure

Comparison of the Effects of Tenofovir Alafenamide and Entecavir on Lipid Profiles in Anti-HBc Positive Kidney Transplant Recipients (APASL 2026) - No abstract available

Clinical • Transplantation

Comparative Evaluation of Serological, Virological, and Biochemical Outcomes in Chronic Hepatitis B Patients Receiving Tenofovir or Entecavir (APASL 2026) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Effects of Switching from Tenofovir Alafenamide Fumarate to Tenofovir Disoproxil Fumarate or Entecavir on Lipid Parameters and Atherosclerotic Cardiovascular Disease Risk (APASL 2026) - No abstract available

Atherosclerosis • Cardiovascular

Long-Term HBsAg Kinetics and Prognostic Significant in Patients with Compensated Cirrhosis: A 13-year Prospective Cohort on Entecavir Therapy (APASL 2026) - No abstract available

Clinical • Fibrosis • Hepatology • Immunology

Comparison of Long-term Efficacy and Renal Safety between Entecavir and Tenofovir Alafenamide Fumarate in Treatment-naive Patients with Chronic Hepatitis B (APASL 2026) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Bushen granule plus entecavir improved the effectiveness for HBeAg negative chronic hepatitis B: A multicenter, randomized, double-blind, placebo-controlled clinical trial (APASL 2026) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Efficacy of Sequential or Combined Tenofovir Alafenamide in Entecavir-Treated CHB Patients with Low-Level Viremia and Its Impact on Lipid Levels (APASL 2026) - No abstract available

Clinical • Hepatitis B

Dynamics of Fibrosis Regression and Long-term Liver-related Events in Patients with Compensated Cirrhosis: A 13-year Prospective Cohort on Entecavir Therapy (APASL 2026) - No abstract available

Clinical • Fibrosis • Hepatology • Immunology

Investigation of the effects of antivirals used in hepatitis B treatment on blood lipid profile: a retrospective real-life data analysis. (PubMed, Minerva Gastroenterol (Torino)) - "TDF causes a decrease in LDL levels, TC and total cholesterol/HDL ratio. However, use of ETV and TAF did not significantly affect the lipid profile. It should not be forgotten that lipid profile changes may cause metabolic health problems in individuals receiving hepatitis B treatment and appropriate treatment should be planned by regular monitoring according to treatment groups."

Journal • Retrospective data • Dyslipidemia • Hepatitis B • Infectious Disease • Inflammation

VAYHIA: A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia (clinicaltrials.gov) - P3 | N=90 | Recruiting | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Recruiting

Enrollment open • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology

Diabetes Impairs the Virological Response in Patients with Chronic Hepatitis B: Glycemic Control as a Key Modifiable Risk Factor. (PubMed, J Clin Med) - "Regarding antiviral regimens, entecavir-treated CHB + T2DM patients had a lower CVR than CHB controls (18.8% vs. 46.2%, p = 0.015)...Optimal glycemic control may improve virological outcomes. These findings suggest that the early diagnosis and management of T2DM could enhance antiviral treatment efficacy in CHB patients."

Journal • Diabetes • Hepatitis B • Infectious Disease • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus